Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Best practices in global flow cytometry quality control and harmonisation

    5 March 2026. Register today.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Showing 865 - 876 of 955 results for "*"

Social media image
ICON Plc logo
ICON Plc

Integrating modern technologies and scientific advances into cardiovascular outcomes trials can streamline their execution and improve efficiency. Find an overview of tools and strategic approaches sponsors can use to ma...

17 Sep
Social media image
ICON Plc logo
ICON Plc

Andrew Roche, Senior Director of Scientific Affairs, will be speaking at the Biomarkers & Precision Medicine conference on 1 October at 2:50 PM. In his session, “Key considerations for high-quality data generation in g...

17 Sep
ICON Plc facebook post
ICON Plc logo
ICON Plc

Discover how ICON’s #drug development experts, using advanced modelling and simulation, assessed the clinical hypothesis and identified opportunities to simplify the development path. https://ow.ly/COWp50WNlMe #ICONEx...

17 Sep
1
Social media image
ICON Plc logo
ICON Plc

Discover how ICON’s #drug development experts, using advanced modelling and simulation, assessed the clinical hypothesis and identified opportunities to simplify the development path. https://ow.ly/Et7850WNlM9 #ICONEx...

17 Sep
Social media image
ICON Plc logo
ICON Plc

ICON's new CEO speaks to BioXconomy on industry challenges - and opportunities - ahead. Discover more: https://ow.ly/zY9y50WXGUW

17 Sep
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON's new CEO speaks to BioXconomy on industry challenges - and opportunities - ahead. Discover more: https://ow.ly/S6I650WXGUX

17 Sep
12
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON’s Victoria DeVeaugh-Geiss, Director of Clinical Operations, will share insights on holistic risk management in clinical trials and explore how evolving RBQM and RBDM strategies can drive cross-functional success. ht...

17 Sep
4
Social media image
ICON Plc logo
ICON Plc

ICON’s Victoria DeVeaugh-Geiss, Director of Clinical Operations, will share insights on holistic risk management in clinical trials and explore how evolving RBQM and RBDM strategies can drive cross-functional success. ht...

17 Sep
ICON Plc facebook post
ICON Plc logo
ICON Plc

Accelerating access to innovative therapies is more than a regulatory ambition—it’s a strategic imperative for sponsors navigating global approvals. From FDA’s Project Orbis to EMA’s PRIME and WHO’s Collaborative Registr...

16 Sep
1
Social media image
ICON Plc logo
ICON Plc

Faster access to life-saving therapies is within reach. Global regulators are working together to speed approvals for oncology and rare disease treatments—but navigating these pathways takes foresight and expertise. Ou...

16 Sep
Social media image
ICON Plc logo
ICON Plc

The #EASD2025 Annual Meeting is now underway at VIECON in Vienna. Adam Amory, Valerio Adinolfi, and Danica Kićevac are welcoming attendees at booth #E1.02 in Hall B of the exhibition area. We invite you to stop by to dis...

16 Sep
ICON Plc facebook post
ICON Plc logo
ICON Plc

Meaningful outcomes in obesity trials go beyond the scale. By integrating COAs and DHTs, sponsors can capture real-world, patient-centered insights that improve both regulatory alignment and trial value. Join us on Oct...

16 Sep
  • Previous
  • 1
  • …
  • 72
  • 73
  • 74
  • …
  • 80
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence